Cerus (STU:CU2) Institutional Ownership : 55.27% (As of May. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Cerus Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cerus's institutional ownership is 55.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cerus's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cerus's Float Percentage Of Total Shares Outstanding is 74.80%.

Cerus Institutional Ownership Historical Data

The historical data trend for Cerus's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Institutional Ownership Chart

Cerus Historical Data

The historical data trend for Cerus can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	63.08	62.97	59.87	57.09	56.71	57.31	56.89	56.78	55.66	55.27

Cerus Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Cerus (STU:CU2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (STU:CU2) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CERS:USA

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (STU:CU2) Headlines

No Headlines